Tenofovir Nephrotoxicity: 2011 Update

被引：227

作者：

Fernandez-Fernandez, Beatriz ^{[1
]}

Montoya-Ferrer, Ana ^{[2
]}

Sanz, Ana B. ^{[3
]}

Sanchez-Nino, Maria D. ^{[3
]}

Izquierdo, Maria C. ^{[1
]}

Poveda, Jonay ^{[1
]}

Sainz-Prestel, Valeria ^{[1
]}

Ortiz-Martin, Natalia ^{[1
]}

Parra-Rodriguez, Alejandro ^{[1
]}

Selgas, Rafael ^{[3
]}

Ruiz-Ortega, Marta ^{[1
]}

Egido, Jesus ^{[1
]}

Ortiz, Alberto ^{[1
,4
]}

机构：

[1] Univ Autonoma Madrid, FRIAT, IRSIN, IIS Fdn Jimenez Diaz,Nefrol, Madrid, Spain

[2] IIS Fdn Jimenez Diaz, Med Interna, Madrid, Spain

[3] Univ Autonoma Madrid, FRIAT, IRSIN, IDiPaz,Nefrol, Madrid, Spain

[4] Fdn Jimenez Diaz, Unidad Dialisis, Madrid 28040, Spain

来源：

AIDS RESEARCH AND TREATMENT | 2011年 / 2011卷

关键词：

D O I：

10.1155/2011/354908

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Tenofovir is an acyclic nucleotide analogue reverse-transcriptase inhibitor structurally similar to the nephrotoxic drugs adefovir and cidofovir. Tenofovir is widely used to treat HIV infection and approved for treatment of hepatitis B virus. Despite initial cell culture and clinical trials results supporting the renal safety of tenofovir, its clinical use is associated with a low, albeit significant, risk of kidney injury. Proximal tubular cell secretion of tenofovir explains the accumulation of the drug in these mitochondriarich cells. Tenofovir nephrotoxicity is characterized by proximal tubular cell dysfunction that may be associated with acute kidney injury or chronic kidney disease. Withdrawal of the drug leads to improvement of analytical parameters that may be partial. Understanding the risk factors for nephrotoxicity and regular monitoring of proximal tubular dysfunction and serumcreatinine in high-risk patients is required tominimize nephrotoxicity. Newer, structurally similarmolecular derivatives that do not accumulate in proximal tubules are under study.

引用

页数：11

共 83 条

[71] Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study [J].

Rodriguez-Novoa, Sonia ;

Labarga, Pablo ;

Soriano, Vincent ;

Egan, Deirdre ;

Albalater, Marta ;

Morello, Judit ;

Cuenca, Lorena ;

Gonzalez-Pardo, Gema ;

Khoo, Saye ;

Back, David ;

Owen, Andrew .

CLINICAL INFECTIOUS DISEASES, 2009, 48 (11) :E108-E116

[72] The expanding spectrum of biological actions of vitamin D [J].

Rojas-Rivera, Jorge ;

De La Piedra, C. ;

Ramos, Ana ;

Ortiz, Alberto ;

Egido, Jesus .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (09) :2850-2865

[73] Understanding estimated glomerular filtration rate: implications for identifying chronic kidney disease [J].

Rule, Andrew D. .

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2007, 16 (03) :242-249

[74] Mechanisms of renal apoptosis in health and disease [J].

Sanz, Ana Belen ;

Santamaria, Beatriz ;

Ruiz-Ortega, Marta ;

Egido, Jesus ;

Ortiz, Alberto .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 19 (09) :1634-1642

[75]

Sax PE, 2007, AIDS READ, V17, P90

[76] Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study [J].

Schooley, RT ;

Ruane, P ;

Myers, RA ;

Beall, G ;

Lampiris, H ;

Berger, D ;

Chen, SS ;

Miller, MD ;

Isaacson, E ;

Cheng, AK .

AIDS, 2002, 16 (09) :1257-1263

[77] Mitochondrial DNA replication and disease: insights from DNA polymerase γ mutations [J].

Stumpf, Jeffrey D. ;

Copeland, William C. .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2011, 68 (02) :219-233

[78] Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion [J].

Tanji, N ;

Tanji, K ;

Kambham, N ;

Markowitz, GS ;

Bell, A ;

D'Agati, VD .

HUMAN PATHOLOGY, 2001, 32 (07) :734-740

[79] Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques [J].

Van Rompay, KKA ;

Brignolo, LL ;

Meyer, DJ ;

Jerome, C ;

Tarara, R ;

Spinner, A ;

Hamilton, M ;

Hirst, LL ;

Bennett, DR ;

Canfield, DR ;

Dearman, TG ;

Von Morgenland, W ;

Allen, PC ;

Valverde, C ;

Castillo, AB ;

Martin, RB ;

Samii, VF ;

Bendele, R ;

Desjardins, J ;

Marthas, ML ;

Pedersen, NC ;

Bischofberger, N .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (05) :1469-1487

[80] Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy [J].

Winston, A ;

Amin, J ;

Mallon, PWG ;

Marriott, D ;

Carr, A ;

Cooper, DA ;

Emery, S .

HIV MEDICINE, 2006, 7 (02) :105-111

← 1 2 3 4 5 6 7 8 9 →